Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More
Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More
Psyched：1億美元用於搖頭丸療法、弗吉尼亞州基金、2024年觀察名單、改革更新等
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD
迷幻藥開發商獲得1億美元的A輪融資，將支持MDMA批准治療創傷後應激障礙
A decade after it was founded as a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), MAPS Public Benefit Corporation has secured over $100 million in a Series A private stock sale. The funds will support the final stages of its application for regulatory approval to sell MDMA, also known as ecstasy, as a treatment for post-traumatic stress disorder (PTSD).
作爲迷幻研究多學科協會（MAPS）的全資子公司成立十年後，MAPS公益公司已通過A輪私募股票出售獲得了超過1億美元的融資。這筆資金將支持其申請監管部門批准出售搖頭丸（也稱爲搖頭丸）作爲創傷後應激障礙（PTSD）治療藥物的最後階段。
MAPS has incubated the only psychedelic-assisted therapy research program that has completed two successful Phase 3 studies and submitted a New Drug Application...
MAPS已經孵化了唯一一個成功完成兩項3期研究...
登入免費觀看全文
登入/註冊